Showing 2371-2380 of 5696 results for "".
- Tarsus Announces Positive Topline Data from Saturn-2 Phase 3 Trial of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-announces-positive-topline-data-from-saturn-2-phase-3-the-second-pivotal-trial-of-tp-03-for-the-treatment-of-demodex-blepharitis/2480827/Tarsus Pharmaceuticals announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal phase 3 trial with a favorable safety profile, reinforcing its ability to resolve Demodex blepharitis. With these
- SightGlass Vision Presents 24-Month Data Demonstrating Myopia Control Efficacy for Vision Spectacle Lenseshttps://modernod.com/news/sightglass-vision-presents-24-month-data-demonstrating-myopia-control-efficacy-for-vision-spectacle-lenses/2480823/Spectacles that use SightGlass Vision Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children,[1] based on 24-month interim data from its pivotal c
- Nicox Presents Phase 2 Results on NCX 4251 and New Nonclinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470https://modernod.com/news/nicox-presents-phase-2-results-on-ncx-4251-and-new-nonclinical-evidence-of-improved-hemodynamic-and-retinal-cell-physiology-on-ncx-470/2480822/Nicox SA announced poster presentations highlighting the effect of NCX 4251 in patients with dry eye disease as well as new nonclinical evidence of neuroprotective activity on NCX 470 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 annual meeting, one of the key scien
- Registration Now Open for Neuro-Optometric Rehabilitation Association Annual Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-annual-conference/2480810/Registration is now open for the Neuro-Optometric Rehabilitatio
- Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022https://modernod.com/news/tarsus-presents-results-of-two-studies-highlighting-demodex-blepharitis-patient-impact-and-burden-at-the-ascrs-2022-annual-meeting/2480803/Tarsus Pharmaceuticals presented data from its Atlas Continuation study on the negative impacts to daily life and visual function, and preliminary findings from its Pandora study on pathogenic bacterial count, for patients with Demodex blepharitis at the American S
- CorneaGen Releases New DSEK Surgery Device to Help Streamline DSEK Surgerieshttps://modernod.com/news/corneagen-advances-next-generation-of-dsek-surgery-innovation/2480789/CorneaGen announced the release of the EndoSerter-PL, a new FDA approved, single-use graft insertion device preloaded with processed tissue to help streamline DSEK surgeries. “We’re incredibly excited to deliver the EndoSerter-PL, our latest innovation in
- Centricity Vision Announces New Technologies Under Development, Zeptolink and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&Dhttps://modernod.com/news/centricity-vision-announces-new-technologies-under-development-zeptolink-and-55-mm-capsulotomy-names-leonard-borrmann-to-lead-rd/2480783/Centricity Vision announced two product innovations under development, the Zeptolink platform and Zepto 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, PharmD, to lead research and development. "The Zepto technology is elevating the precisi
- Zeiss Announces FDA Clearance of the Quatera 700 Phaco Devicehttps://modernod.com/news/zeiss-announces-fda-clearance-of-the-quatera-700-phaco-technology/2480779/Zeiss announced that the FDA has cleared the Quatera 700, which includes the Zeiss patented Quattro Pump designed to deliver chamber stability independent of IOP and flow. “What excites me the most about the Quatera 700 is the Quattro pump’
- Market Scope: Robotic Vitrectomy Debate Still Rages for Retina Surgeonshttps://modernod.com/news/market-scope-robotic-vitrectomy-debate-still-rages-for-retina-surgeons/2480773/The future of robotic vitrectomy continues to be top of mind for retina surgeons, with panelists at nearly every major retina meeting in 2021 debating the topic—and without reaching co
- Study Lays Foundation for Establishing Base Editing as a One-Time, Durable Treatment for Inherited Retinal Degenerationhttps://modernod.com/news/study-lays-foundation-for-establishing-base-editing-as-a-one-time-durable-treatment-for-inherited-retinal-degeneration/2480766/A new University of California, Irvine-led study indicates base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis (LCA) patients. “Our findings demo